Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.

@article{Furumatsu2008IntegratedTI,
  title={Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.},
  author={Yoshiyuki Furumatsu and Yasuyuki Nagasawa and Takayuki Hamano and Hirotsugu Iwatani and Kenichiro Iio and Tatsuya Shoji and Takahito Ito and Yoshiharu Tsubakihara and Enyu Imai},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2008},
  volume={23 3},
  pages={984-90}
}
BACKGROUND Erythropoietin (EPO) has been reported to slow the decline of renal function in predialysis chronic kidney disease (CKD) patients. On the contrary, in the recent large-scale randomized controlled trial (RCT), CREATE and CHOIR, which aimed to keep a higher haemoglobin (Hb) level than former trials, the renoprotective effect of EPO was not observed. Today, the renoprotective effect of EPO has become controversial. In order to test the hypothesis that the usage of EPO in predialysis CKD… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Geographic differences in the increasing ESRD rate have disappeared in Japan

Clinical and Experimental Nephrology • 2011
View 3 Excerpts
Highly Influenced

FGF23 modulates the effects of erythropoietin on gene expression in renal epithelial cells

International journal of nephrology and renovascular disease • 2018
View 1 Excerpt

Specialist care and improved long-term survival of dialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…